Rapid reconstitution of Epstein-Barr virus–specific T lymphocytes following allogeneic stem cell transplantation
Open Access
- 15 October 2000
- journal article
- Published by American Society of Hematology in Blood
- Vol. 96 (8) , 2814-2821
- https://doi.org/10.1182/blood.v96.8.2814
Abstract
Epstein-Barr virus (EBV)–specific CD8 T lymphocytes are present at remarkably high frequencies in healthy EBV+individuals and provide protection from EBV-associated lymphoproliferative diseases. Allogeneic peripheral blood stem cell transplantation (allo-PBSCT) is a commonly used therapy in which T-cell surveillance for EBV is temporarily disrupted. Herein, human leukocyte antigen (HLA) class I tetramers were used to investigate the reestablishment of the EBV-specific CD8 T-cell repertoire in patients following allo-PBSCT. CD8+ T cells specific for lytic and latent cycle–derived EBV peptides rapidly repopulate the periphery of matched sibling allo-PBSCT patients. The relative frequencies of T cells specific for different EBV peptides in transplantation recipients closely reflect those of their respective donors. Investigation of patients at monthly intervals following unmanipulated allo-PBSCT demonstrated that the frequency of EBV-specific T cells correlates with the number of EBV genome copies in the peripheral blood and that expansion of EBV-specific T-cell populations occurs even in the setting of immunosuppressive therapy. In contrast, patients undergoing T-cell–depleted or unrelated cord blood transplantation have undetectable EBV-specific T cells, even in the presence of Epstein-Barr viremia. The protective shield provided by EBV-specific CD8 T cells is rapidly established following unmanipulated matched sibling allo-PBSCT and demonstrates that HLA class I tetramers complexed with viral peptides can provide direct and rapid assessment of pathogen-specific immunity in this and other vulnerable patient populations.Keywords
This publication has 40 references indexed in Scilit:
- Epstein–Barr virus-associated lymphoproliferative disease after a cord blood transplant for Diamond–Blackfan anemiaBone Marrow Transplantation, 2000
- First report of Epstein-Barr virus lymphoproliferative disease after cord blood transplantationBone Marrow Transplantation, 2000
- Changes in Frequency of HIV‐1–Specific Cytotoxic T Cell Precursors and Circulating Effectors after Combination Antiretroviral Therapy in ChildrenThe Journal of Infectious Diseases, 1999
- Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNAScience, 1998
- HUMAN CYTOTOXIC T LYMPHOCYTE RESPONSES TO EPSTEIN-BARR VIRUS INFECTIONAnnual Review of Immunology, 1997
- Bone marrow transplantation for therapy in autoimmune diseaseThe International Journal of Cell Cloning, 1997
- The Use of Mobilized Peripheral Blood Stem Cells from Normal Donors for AllograftingThe International Journal of Cell Cloning, 1997
- The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4.The Journal of Experimental Medicine, 1996
- Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell ClonesScience, 1992
- Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for LeukemiaNew England Journal of Medicine, 1986